MedTrace Logo

Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer

NCT02418312 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2019-03-11

Study results available
· View outcomes & findings →

Summary

Whether H2 receptor antagonist can prevent thienopyridine-related peptic ulcer remains unclear.

Conditions

  • Peptic Ulcer

Interventions

DRUG

histamine-2 receptor antagonist

famotidine 40 mg qd plus thienopyridine

DRUG

Placebo

placebo plus thienopyridine

Sponsors & Collaborators

  • Kaohsiung Veterans General Hospital.

    lead OTHER

Principal Investigators

  • Ping-I Hsu, Bachelor · Kaohsiung Veterans General Hospital.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02418312 on ClinicalTrials.gov